THAZ

THAZ, also known as 5,6,7,8-tetrahydro-4H-isoxazoloazepin-3-ol, is a moderately potent GABA_A-ρ receptor antagonist related to gaboxadol. Unlike gaboxadol, it is said to be virtually inactive at the GABA_A receptor. However, in other studies, it showed significant affinity for the GABA_A receptor, where it appeared to act as an antagonist. In addition to its GABA_A-ρ receptor antagonism, THAZ is a very weak glycine receptor antagonist. In contrast to muscimol and gaboxadol, THAZ injected directly into the brain produced convulsions. The drug was first described in the scientific literature by Povl Krogsgaard-Larsen and colleagues by 1979. Derivatives of THAZ such as N-Bn-THAZ and O-Bn-THAZ have been found to act as serotonin 5-HT_2A and 5-HT_2C receptor agonists.